New clinical report challenges assumptions about embryo viability and highlights the complexity of PGT-A interpretation

The first documented birth of healthy twins following the transfer of embryos diagnosed as aneuploid has been reported, adding an important data point to the ongoing discussion about the limitations of preimplantation genetic testing for aneuploidy. The findings come from a case report published in Fertility and Sterility and summarised by EMJ Reviews. Together, they describe a scenario that underscores how embryo genetics, early developmental dynamics, and biopsy sampling can interact in unexpected ways.

The case involved a patient who underwent IVF with PGT-A. Two blastocysts were classified as aneuploid by trophectoderm biopsy. Both embryos were transferred after counselling, and both implanted. The pregnancy progressed normally, and the patient delivered healthy twins with no structural anomalies. Postnatal karyotyping confirmed that the twins were chromosomally normal.

This outcome reinforces the growing understanding that a trophectoderm biopsy represents only a small fraction of the embryo. False positive aneuploid calls can occur if the sampled cells contain mosaic or transient abnormalities that are not representative of the inner cell mass, which forms the fetus. As the field has recognised in recent years, some embryos labelled as aneuploid may still have the developmental capacity to self-correct or may have had normal ICM lineages from the start.

The authors emphasise that this report does not suggest routine transfer of embryos diagnosed as aneuploid. Instead, it highlights the need for careful counselling and the importance of ongoing research into the predictive value of PGT-A. Clinicians continue to debate how best to interpret low-level mosaicism, segmental abnormalities, and complex profiles, especially when patients have limited embryos available for transfer.

From a scientific standpoint, this case provides further evidence that embryo genetics is more nuanced than binary categories can capture. The discordance between the biopsy result and the clinical outcome underscores the importance of technical precision, biological variability, and thoughtful interpretation.

For IVF laboratories and clinicians, the report ultimately serves as a reminder that the embryo is a dynamic system. While PGT-A remains a widely used screening tool, individual outcomes like this one highlight the need for continued refinement of testing methods and more robust data to guide clinical decision-making.

Sources